Literature DB >> 6745104

[Central hemodynamics of antihypertensive agents. Studies on co-dergocrinmesylate].

D Welzel, G Weidinger, K Koppenhagen.   

Abstract

The haemodynamic effects of a three-week-treatment with 4-8 mg co-dergocrinmesylate (Hydergin spezial) were investigated in 14 hypertensive patients with a mean age of 58 years and reduced ventricular function (exertional dyspnoea, enlarged cardiac opacity). Blood pressure values at rest and during physical exercise were reduced significantly. Marked cardiac relief was induced manifesting as decrease of enddiastolic and endsystolic volumes and at the same time as an increase of ejection fraction. Cardiac output remained largely constant, lowering of blood pressure was exclusively due to alteration of peripheral total vascular resistance. Cardiac frequency decreased significantly. There was no evidence of negative inotropic effects. Systolic wall tension as the main therapeutic target decreased at rest and during ergometry by 20% and 25%, respectively. Renal perfusion increased slightly, but significantly, in all patients.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6745104     DOI: 10.1055/s-2008-1069325

Source DB:  PubMed          Journal:  Dtsch Med Wochenschr        ISSN: 0012-0472            Impact factor:   0.628


  1 in total

1.  Clinical pharmacokinetics of the nifedipine/co-dergocrine combination in impaired liver and renal function.

Authors:  W Kirch; A Nokhodian; A Halabi; G Weidinger
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1992 Jan-Mar       Impact factor: 2.441

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.